Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.

As more people turn to GLP-1 agonists (such as semaglutide) for weight loss, nutrient deficiencies appear to be rising. Although hard data doesn’t yet exist on how many people taking Ozempic ...

The uptake of GLP-1 has surged since 2022, mainly in US. Read our takeaways from the UBS Evidence Lab survey on key trends in GLP-1 consumer behaviour GLP-1s, also known as glucagon-like peptide 1, ...

You may soon be able to eat your Ozempic … sort of. GLP-1 supplements are booming, promising to deliver similar benefits to Ozempic and Wegovy without the pricey injections. The latest contender ...

At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

When Laurie was diagnosed with diabetes, her heart sank. “My diabetes marker A1C was so high that my doctor told me that I could stroke out at any moment. If that doesn’t scare someone, I don ...

The culprit? Popular weight-loss drugs like Ozempic, which mimic the hormone glucagon-like peptide-1 (GLP-1) to curb hunger. But these medications aren’t just suppressing appetites. They’re ...

To study how GLP-1 receptor agonists affect muscle and fat, the HKUMed research team used genetic data of over 800,000 European participants from different genome wide association studies (GWAS).

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...

Food companies behind everything from canned soup to frozen dinners are trying to win over a growing group: people who are eating less because of their GLP-1 medications. General Mills ...

“The body of evidence for the GLP-1 drug class shows that up to 40% of total weight loss in GLP-1 patients is lean body mass including skeletal muscle mass, 1 ” said Mitchell Glass, M.D ...